Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

(2010) M. Reck et al.   ANNALS OF ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

(2010) Adrian M Jubb et al.   LANCET ONCOLOGY

Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer

(2009) A M Jubb et al.   BRITISH JOURNAL OF CANCER

Bevacizumab Safety in Patients with Central Nervous System Metastases

(2009) B. Besse et al.   CLINICAL CANCER RESEARCH

Safety of Bevacizumab in Patients With Non–Small-Cell Lung Cancer and Brain Metastases

(2009) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Diffusion Magnetic Resonance Imaging Detects Pathologically Confirmed, Nonenhancing Tumor Progression in a Patient With Recurrent Glioblastoma Receiving Bevacizumab

(2009) Elizabeth R. Gerstner et al.   JOURNAL OF CLINICAL ONCOLOGY

Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107

(2008) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE